ISRCTN76747656已完成不适用
A phase II randomised study of cisplatinum and nifedipine in end stage carcinoma of the head and neck
orth West Cancer Research Fund (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with either advanced squamous cell carcinoma of the head and neck, not previously treated, or recurrent squamous cell carcinoma of the head and neck after previous radiotherapy or surgery
- •2. Measurable histologically confirmed, squamous cell carcinoma of the head and neck. The primary sites will be:
- •2.1. Mouth
- •2.2. Nasopharynx
- •2.3. Oropharynx
- •2.4. Hypopharynx
- •2.5. Larynx
- •2.6. Nose and sinuses
- •2.7. Middle ear
- •3. No prior chemotherapy
- •4. Not suitable for surgery or radiotherapy with a curative purpose
- •5. Karnofsky performance greater than 50
- •6. Minimum of three weeks since prior radiotherapy and or surgery and patients must have fully recovered from such prior treatments
- •7. Adequate bone marrow and renal function
- •8. No active infection
- •9. No concomitant or prior malignancy except adequately treated basal cell carcinoma of the skin and in situ carcinoma of the uterine cervix
排除标准
- •Not provided at time of registration
研究者
相似试验
尚未招募
2 期
ANTS Trial (Australian Neoadjuvant Therapy Study for Non-small Cell Lung Cancer)ACTRN12608000061336Austin Health100
已完成
2 期
A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment consisting of chemoradiotherapy followed by surgery (OLCSG1601)previously untreated non-small-cell lung ccancer, stage III (N2 positive)JPRN-UMIN000024816Okayama Lung Cancer Study Group (OLCSG)80
已完成
3 期
Randomized, comparative clinical study of cisplatin and docetaxel combination chemotherapy and mitomycin, vindesine and cisplatin (MVP) combination chemotherapy with concurrent thoracic radiation therapy for locally advanced unresectable non-small-cell lung cancer (OLCSG0007)inoperable locally advanced non-small-cell lung cancerJPRN-C000000085Okayama Lung Cancer Study Group (OLCSG)200
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusEUCTR2019-000308-13-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)180
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusOropharyngeal Squamous Cell CarcinomaMedDRA version: 20.1Level: LLTClassification code 10079785Term: Oropharyngeal squamous cell carcinoma stage IVSystem Organ Class: 100000004864EUCTR2019-000308-13-ITEuropean Organisation for Research and Treatment of Cancer (EORTC)180